New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2013
15:34 EDTMXIM, EMN, CERN, SBUX, EXPE, ALTR, RSG, CB, AMZN, VRSN, KLAC, PFG, RRC, BIDU, BMRNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Amazon (AMZN), consensus 9c; Starbucks (SBUX), consensus 48c; Baidu (BIDU), consensus $1.03; Chubb (CB), consensus $1.74; Cerner (CERN), consensus 63c; Range Resources (RRC), consensus 28c; Republic Services (RSG), consensus 40c; Eastman Chemical (EMN), consensus $1.57; Principal Financial Group (PFG), consensus 74c; Altera (ALTR), consensus 33c; Maxim Integrated Products (MXIM), consensus 42c; KLA-Tencor (KLAC), consensus 86c; Expedia (EXPE), consensus 23c; BioMarin Pharmaceutical (BMRN), consensus (29c); VeriSign (VRSN), consensus 54c.
News For AMZN;SBUX;BIDU;CB;CERN;RRC;RSG;EMN;PFG;ALTR;MXIM;KLAC;EXPE;BMRN;VRSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
March 17, 2015
09:07 EDTAMZNDISH's Sling TV launches on Xbox One
Subscribe for More Information
09:05 EDTAMZNMicrosoft Band now available at Best Buy, Target, Amazon, Re/code reports
Subscribe for More Information
07:42 EDTAMZNBoeing may produce satellite for tech giants, Reuters says
Subscribe for More Information
07:18 EDTBMRNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
March 16, 2015
16:00 EDTAMZNOptions Update; March 16, 2015
Subscribe for More Information
11:58 EDTEMNDuPont retreats after Bank of America two notch downgrade to sell
Subscribe for More Information
10:44 EDTAMZNNetflix retreats after cut to sell on competition, cost concerns
The shares of Netflix (NFLX) are falling after research firm Evercore ISI downgraded the stock to Sell from Hold. Increased competition will force the company to increase its investments and the return from those investments is uncertain, the firm contends. WHAT'S NEW: In the U.S., technological advancements are enabling content providers to sell their programming to a wider range of Internet video distributors, Evercore ISI analyst Ken Sena wrote in a note to investors earlier today. Moreover, content providers themselves are now able to stream more of their programming online and obtain higher profits from doing so, Sena reported. The analyst noted that Apple (AAPL) recently obtained a three month exclusive deal to stream content form Time Warner's (TWX) HBO Now, while Yahoo (YHOO), Amazon (AMZN), and Hulu (DIS, CMCSA, NWSA) are all reportedly interested in obtaining streaming rights to "Seinfeld." Netflix's international expansion will not be sufficient to offset the increased competition, especially because foreign viewers are likely to watch less TV and be less interested in paying for TV content, the analyst believes. Furthermore, Netflix will face more competition from other Internet TV services overseas than in the U.S., according to Sena, who cut his 2015 consolidated operating income estimate for the company by 26% to $381M from $517M previously. In addition to cutting his rating, Sena lowered his price target on the shares to $380 from $450. PRICE ACTION: In early trading, Netflix sank $16, or 3.7%, to $422.
10:28 EDTBMRNOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
10:02 EDTEMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:45 EDTEMN, EMNEastman Chemical downgraded to Underperform from Outperform at CLSA
March 13, 2015
17:11 EDTAMZNSony Pictures TV nears streaming video deal for Seinfeld, WSJ reports
Subscribe for More Information
16:01 EDTAMZNOptions Update; March 13, 2015
Subscribe for More Information
13:38 EDTMXIM, ALTRNXP climbs after analyst says Freescale deal creates semiconductor 'powerhouse'
Subscribe for More Information
11:19 EDTBMRNBioMarin rallies amid positive call on DMD drug timeline, takeover rumor
The shares of drug maker BioMarin (BMRN) are climbing after research firm Jefferies quoted a regulatory expert as saying that the company's drisapersen drug has a good chance of being approved on an accelerated basis by the FDA. Drisapersen is a treatment for Duchenne Muscular Dystrophy, or DMD. WHAT'S NEW: "There is a strong possibility" that the FDA will grant accelerated approval to drisapersen because there is currently no approved drug for the treatment of DMD, Jefferies analyst Eun Yang quoted the expert as saying. The expert is also optimistic about the outlook for accelerated approval because she had a good experience working with BioMarin while she was with the FDA and because BioMarin has a favorable track record with the FDA, according to Yang. There is a 60% chance that drisapersen will be approved by the end of this year and the stock can rise to $155, versus its current level of about $121.50, if that does occur, the analyst stated. Yang's price target on the stock increased to $135 from $125 and the analyst kept a Buy rating on the shares. WHAT'S NOTABLE: Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash, British newspaper Daily Mail reported. , Piper Jaffray analyst Joshua Schimmer wrote in a note to investors this morning that BioMarin, along with Vertex (VRTX) and Incyte (INCY), have a "clear path" to joining the group of companies with market caps of over $10B projected to deliver greater than 20% EPS CAGR, which the analyst identified as a set of criteria that has previously pointed to companies that make good potential takeover targets. PRICE ACTION: In mid-morning trading, BioMarin climbed nearly 4% to $120.
10:34 EDTAMZNApple joins data center group with Facebook, Microsoft, The Information says
Subscribe for More Information
10:09 EDTBMRNHigh option volume stocks
High option volume stocks: ULTA HOG CTIC CTL LOCO IMPV BMRN IMOS ATHX GALE
09:50 EDTAMZNActive equity options trading on open
Subscribe for More Information
08:07 EDTBMRNAstraZeneca rumored to have BioMarin 'on shopping list,' Daily Mail says
Subscribe for More Information
07:39 EDTBMRNBioMarin price target raised to $135 from $125 at Jefferies
Jefferies raised its price target for BioMarin shares to $135 after a regulatory expert it spoke to expressed optimism regarding drisapersen winning accelerated approval. Jefferies sees greater than 30% upside to current share levels should drisapersen get approved by the end of 2015. The firm views BioMarin as well positioned for "meaningful" long-term growth and keeps a Buy rating on the name.
06:03 EDTAMZNStocks with implied volatility below IV index mean; AMZN QCOM
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use